T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts

BackgroundChimeric antigen receptor (CAR)-T cell therapy has established itself as a potent therapeutic option for certain patients with relapsed/refractory (R/R) hematologic malignancies. To date, four CD19-redirected CAR-T cell products have been granted the United States Food and Drug Administrat...

Full description

Bibliographic Details
Main Authors: Fatemeh Nasiri, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor
CD19
cancer immunotherapy
hematologic malignancy
VHH
scFv
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1063838/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1063838/full

Similar Items